New Positive Clinical Data mu Odwala omwe Ali ndi Khansa Yam'mimba

Written by mkonzi

Mirati Therapeutics, Inc., kampani yolimbana ndi matenda a oncology, lero yalengeza zotsatira zabwino kuchokera ku gulu la Phase 2 la kafukufuku wa KRYSTAL-1 wowunika adagrasib pa mlingo wa 600mg BID mwa odwala omwe ali ndi pretreated pancreatic ductal adenocarcinoma ndi zotupa zina zam'mimba (GI). kukhala ndi kusintha kwa KRASG12C, kuphatikiza makhansa a biliary thirakiti, appendix, matumbo aang'ono, gastro-esophageal junction, ndi esophagus. Zotsatira zinawonetsa kuti adagrasib adawonetsa zochitika zazikulu zachipatala komanso kuwongolera matenda.

Sangalalani, PDF ndi Imelo

Zomwe zapezedwa (Abstract # 519) zidzaperekedwa lero ku 10: 00 am ET panthawi yachidule cha 2022 American Society for Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium.      

Dr. Tanios S. Bekaii-Saab, wofufuza kafukufuku wa KRYSTAL-1, adanena kuti, "Makhansa a m'mimba ndi ena mwa khansa yofala kwambiri ndipo akupitirizabe kugwirizana ndi zotsatira zoipa za kupulumuka ngakhale kuti zapita patsogolo posachedwapa, makamaka kwa odwala omwe ali ndi zotupa za GI zomwe zimasungidwa. Mtengo wa KRASG12C Deta yatsopano yachipatala yoperekedwa ku ASCO GI ikuwonetsa kuti adagrasib, inhibitor ya KRASG12C, adawonetsa kulonjeza kwachipatala kwa odwala omwe ali ndi khansa ya kapamba ndi zotupa zina za GI. Zomwe zapezazi zimatengera zomwe zidanenedwapo kale zachipatala cha adagrasib mu khansa ya colorectal ndi pancreatic, ndipo ndi zolimbikitsa kwambiri, zikutsimikizira kuti adagrasib afufuzidwanso motere. "

Chidule cha Zotsatira Zachipatala

• Pofika pa Seputembara 10, 2021, gulu laling'ono la odwala omwe ali ndi khansa ya GI okhala ndi kusintha kwa KRASG12C omwe adalembetsa mu adagrasib monotherapy arm (n=30) adalandira njira ziwiri zam'mbuyomu zamachiritso oletsa khansa, ndipo anali ndi kutsata kwapakatikati kwa miyezi 6.3. .

• Mwa odwala omwe amayesedwa (n = 27), chiwerengero cha mayankho (ORR) chinali 41% ndipo chiwerengero cha matenda (DCR) chinali 100%. Odwala oyesedwa omwe ali ndi khansa ya pancreatic (n = 10), chiwerengero cha kuyankha (RR) chinali 50%, kuphatikizapo 1 yankho losatsimikizika lapadera (PR); nthawi yapakatikati yoyankha (mDOR) inali miyezi 7.0, ndikutsata kwapakatikati kwa miyezi 8.1. Odwala omwe ali ndi zotupa zina za GI (n = 17), RR inali 35%, ndi ma PR awiri osatsimikiziridwa; mDOR inali miyezi 7.9 mwa odwalawa, ndikutsatira kwapakatikati kwa miyezi 6.3.

• Kupulumuka kwapakatikati (mPFS) kwa odwala omwe ali ndi khansa ya pancreatic inali miyezi 6.6 (95% Confidence Interval, CI: 1.0, 9.7), ndipo kwa odwala omwe ali ndi zotupa zina za GI, mPFS inali miyezi 7.9 (95% CI 6.90-) 11.30).

• Pagulu lonse la odwala omwe ali ndi khansa ya KRASG12C-mutated GI yomwe idawunikidwa mu gulu ili, adagrasib idaloledwa bwino, yokhala ndi mbiri yotetezedwa. Zotsatira zoyipa zokhudzana ndi chithandizo cha Grade 3/4 (TRAEs) zidawonedwa mu 27% ya odwala omwe amathandizidwa ndi adagrasib, opanda ma TRAE omwe amatsogolera kusimidwa kwamankhwala, ndipo palibe Gulu la 5 TRAEs lomwe adawona.

"Ife timakhulupirira kuti adagrasib ali ndi mamolekyu osiyana, ndipo deta yoperekedwa ku ASCO GI imathandiziranso mbiri yake yomwe ingakhale yabwino kwambiri," adatero Charles M. Baum, MD, Ph.D., woyambitsa, pulezidenti ndi mutu wa kafukufuku ndi kafukufuku. Development, Mirati Therapeutics, Inc. "Zotsatira zake zidawonetsa zochitika zabwino zachipatala kwa odwala omwe ali ndi khansa ya KRASG12C-mutated GI yothandizidwa ndi adagrasib imodzi, makamaka kwa omwe ali ndi khansa ya kapamba komwe zosankha ndizochepa. Tikupitiriza kuwunika kwambiri adagrasib ngati wothandizira mmodzi komanso kuphatikiza ndi mankhwala ena a khansa mu dongosolo lachitukuko chothandizira anthu ambiri omwe ali ndi khansa. "

Sangalalani, PDF ndi Imelo

Ponena za wolemba

mkonzi

Mkonzi wamkulu wa eTurboNew ndi Linda Hohnholz. Amakhala ku eTN HQ ku Honolulu, Hawaii.

Siyani Comment

eTurboNews | | Mbiri ya TravelIndustry